SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001615774-16-007524
Filing Date
2016-10-04
Accepted
2016-10-04 18:30:23
Documents
1
Period of Report
2016-09-09

Document Format Files

Seq Description Document Type Size
1 3 s104277_form3.html 3  
1 3 s104277_form3.xml 3 3129
  Complete submission text file 0001615774-16-007524.txt   4529
Mailing Address C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK NY 10022
Business Address
Oliviero James F III (Reporting) CIK: 0001434718 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-55506 | Film No.: 161920665

Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Issuer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences